2023
Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme
Reuteman-Fowler C, Blahova Z, Ikezawa S, Marder S, Falkai P, Krystal J. Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme. Neuroscience Applied 2023, 2: 102592. DOI: 10.1016/j.nsa.2023.102592.Peer-Reviewed Original Research
2022
Efficacy and safety of BI 425809 in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme
Wunderlich G, Blahova Z, Hake S, Ikezawa S, Marder S, Falkai P, Krystal J. Efficacy and safety of BI 425809 in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme. Neuroscience Applied 2022, 1: 100342. DOI: 10.1016/j.nsa.2022.100342.Peer-Reviewed Original Research